2020
Antaki, Majd; Deufel, Christopher L; Enger, Shirin A.
Fast mixed integer optimization (FMIO) for high dose rate brachytherapy Journal Article
In: Physics in Medicine and Biology, vol. 65, no. 21, pp. 215005, 2020, ISSN: 1361-6560.
Abstract | Links | BibTeX | Tags: Algorithms, Brachytherapy, Computer-Assisted, Humans, Linear Models, Male, Monte Carlo Method, Prostatic Neoplasms, Radiation Dosage, Radiotherapy Dosage, Radiotherapy Planning, Software, Time Factors
@article{antaki_fast_2020,
title = {Fast mixed integer optimization (FMIO) for high dose rate brachytherapy},
author = {Majd Antaki and Christopher L Deufel and Shirin A. Enger},
doi = {10.1088/1361-6560/aba317},
issn = {1361-6560},
year = {2020},
date = {2020-12-01},
journal = {Physics in Medicine and Biology},
volume = {65},
number = {21},
pages = {215005},
abstract = {The purpose of this work was to develop an efficient quadratic mixed integer programming algorithm for high dose rate (HDR) brachytherapy treatment planning problems and integrate the algorithm into an open-source Monte Carlo based treatment planning software, RapidBrachyMCTPS. The mixed-integer algorithm yields a globally optimum solution to the dose volume histogram (DVH) based problem and, unlike other methods, is not susceptible to local minimum trapping. A hybrid linear-quadratic penalty model coupled to a mixed integer programming model was used to optimize treatment plans for 10 prostate cancer patients. Dose distributions for each dwell position were calculated with RapidBrachyMCTPS with type A uncertainties less than 0.2% in voxels within the planning target volume (PTV). The optimization process was divided into two parts. First, the data was preprocessed, in which the problem size was reduced by eliminating voxels that had negligible impact on the solution (e.g. far from the dwell position). Second, the best combination of dwell times to obtain a plan with the highest score was found. The dwell positions and dose volume constraints were used as input to a commercial mixed integer optimizer (Gurobi Optimization, Inc.). A penalty-based criterion was adopted for the scoring. The voxel-reduction technique successfully reduced the problem size by an average of 91%, without loss of quality. The preprocessing of the optimization process required on average 4 s and solving for the global maximum required on average 33 s. The total optimization time averaged 37 s, which is a substantial improvement over the ∼15 min optimization time reported in published literature. The plan quality was evaluated by evaluating dose volume metrics, including PTV D90, rectum and bladder D1cc and urethra D0.1cc. In conclusion, fast mixed integer optimization is an order of magnitude faster than current mixed-integer approaches for solving HDR brachytherapy treatment planning problems with DVH based metrics.},
keywords = {Algorithms, Brachytherapy, Computer-Assisted, Humans, Linear Models, Male, Monte Carlo Method, Prostatic Neoplasms, Radiation Dosage, Radiotherapy Dosage, Radiotherapy Planning, Software, Time Factors},
pubstate = {published},
tppubtype = {article}
}
The purpose of this work was to develop an efficient quadratic mixed integer programming algorithm for high dose rate (HDR) brachytherapy treatment planning problems and integrate the algorithm into an open-source Monte Carlo based treatment planning software, RapidBrachyMCTPS. The mixed-integer algorithm yields a globally optimum solution to the dose volume histogram (DVH) based problem and, unlike other methods, is not susceptible to local minimum trapping. A hybrid linear-quadratic penalty model coupled to a mixed integer programming model was used to optimize treatment plans for 10 prostate cancer patients. Dose distributions for each dwell position were calculated with RapidBrachyMCTPS with type A uncertainties less than 0.2% in voxels within the planning target volume (PTV). The optimization process was divided into two parts. First, the data was preprocessed, in which the problem size was reduced by eliminating voxels that had negligible impact on the solution (e.g. far from the dwell position). Second, the best combination of dwell times to obtain a plan with the highest score was found. The dwell positions and dose volume constraints were used as input to a commercial mixed integer optimizer (Gurobi Optimization, Inc.). A penalty-based criterion was adopted for the scoring. The voxel-reduction technique successfully reduced the problem size by an average of 91%, without loss of quality. The preprocessing of the optimization process required on average 4 s and solving for the global maximum required on average 33 s. The total optimization time averaged 37 s, which is a substantial improvement over the ∼15 min optimization time reported in published literature. The plan quality was evaluated by evaluating dose volume metrics, including PTV D90, rectum and bladder D1cc and urethra D0.1cc. In conclusion, fast mixed integer optimization is an order of magnitude faster than current mixed-integer approaches for solving HDR brachytherapy treatment planning problems with DVH based metrics.
Mao, Ximeng; Pineau, Joelle; Keyes, Roy; Enger, Shirin A.
RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning Journal Article
In: International Journal of Radiation Oncology, Biology, Physics, vol. 108, no. 3, pp. 802–812, 2020, ISSN: 1879-355X.
Abstract | Links | BibTeX | Tags: Brachytherapy, Colon, Computer, Computer-Assisted, Deep Learning, Female, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Neural Networks, Organs at Risk, Prostate, Prostatic Neoplasms, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Retrospective Studies, Sigmoid, Urinary Bladder, Uterine Cervical Neoplasms
@article{mao_rapidbrachydl_2020,
title = {RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning},
author = {Ximeng Mao and Joelle Pineau and Roy Keyes and Shirin A. Enger},
doi = {10.1016/j.ijrobp.2020.04.045},
issn = {1879-355X},
year = {2020},
date = {2020-11-01},
journal = {International Journal of Radiation Oncology, Biology, Physics},
volume = {108},
number = {3},
pages = {802--812},
abstract = {PURPOSE: Detailed and accurate absorbed dose calculations from radiation interactions with the human body can be obtained with the Monte Carlo (MC) method. However, the MC method can be slow for use in the time-sensitive clinical workflow. The aim of this study was to provide a solution to the accuracy-time trade-off for 192Ir-based high-dose-rate brachytherapy by using deep learning.
METHODS AND MATERIALS: RapidBrachyDL, a 3-dimensional deep convolutional neural network (CNN) model, is proposed to predict dose distributions calculated with the MC method given a patient's computed tomography images, contours of clinical target volume (CTV) and organs at risk, and treatment plan. Sixty-one patients with prostate cancer and 10 patients with cervical cancer were included in this study, with data from 47 patients with prostate cancer being used to train the model.
RESULTS: Compared with ground truth MC simulations, the predicted dose distributions by RapidBrachyDL showed a consistent shape in the dose-volume histograms (DVHs); comparable DVH dosimetric indices including 0.73% difference for prostate CTV D90, 1.1% for rectum D2cc, 1.45% for urethra D0.1cc, and 1.05% for bladder D2cc; and substantially smaller prediction time, acceleration by a factor of 300. RapidBrachyDL also demonstrated good generalization to cervical data with 1.73%, 2.46%, 1.68%, and 1.74% difference for CTV D90, rectum D2cc, sigmoid D2cc, and bladder D2cc, respectively, which was unseen during the training.
CONCLUSION: Deep CNN-based dose estimation is a promising method for patient-specific brachytherapy dosimetry. Desired radiation quantities can be obtained with accuracies arbitrarily close to those of the source MC algorithm, but with much faster computation times. The idea behind deep CNN-based dose estimation can be safely extended to other radiation sources and tumor sites by following a similar training process.},
keywords = {Brachytherapy, Colon, Computer, Computer-Assisted, Deep Learning, Female, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Neural Networks, Organs at Risk, Prostate, Prostatic Neoplasms, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Retrospective Studies, Sigmoid, Urinary Bladder, Uterine Cervical Neoplasms},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Detailed and accurate absorbed dose calculations from radiation interactions with the human body can be obtained with the Monte Carlo (MC) method. However, the MC method can be slow for use in the time-sensitive clinical workflow. The aim of this study was to provide a solution to the accuracy-time trade-off for 192Ir-based high-dose-rate brachytherapy by using deep learning.
METHODS AND MATERIALS: RapidBrachyDL, a 3-dimensional deep convolutional neural network (CNN) model, is proposed to predict dose distributions calculated with the MC method given a patient's computed tomography images, contours of clinical target volume (CTV) and organs at risk, and treatment plan. Sixty-one patients with prostate cancer and 10 patients with cervical cancer were included in this study, with data from 47 patients with prostate cancer being used to train the model.
RESULTS: Compared with ground truth MC simulations, the predicted dose distributions by RapidBrachyDL showed a consistent shape in the dose-volume histograms (DVHs); comparable DVH dosimetric indices including 0.73% difference for prostate CTV D90, 1.1% for rectum D2cc, 1.45% for urethra D0.1cc, and 1.05% for bladder D2cc; and substantially smaller prediction time, acceleration by a factor of 300. RapidBrachyDL also demonstrated good generalization to cervical data with 1.73%, 2.46%, 1.68%, and 1.74% difference for CTV D90, rectum D2cc, sigmoid D2cc, and bladder D2cc, respectively, which was unseen during the training.
CONCLUSION: Deep CNN-based dose estimation is a promising method for patient-specific brachytherapy dosimetry. Desired radiation quantities can be obtained with accuracies arbitrarily close to those of the source MC algorithm, but with much faster computation times. The idea behind deep CNN-based dose estimation can be safely extended to other radiation sources and tumor sites by following a similar training process.
METHODS AND MATERIALS: RapidBrachyDL, a 3-dimensional deep convolutional neural network (CNN) model, is proposed to predict dose distributions calculated with the MC method given a patient's computed tomography images, contours of clinical target volume (CTV) and organs at risk, and treatment plan. Sixty-one patients with prostate cancer and 10 patients with cervical cancer were included in this study, with data from 47 patients with prostate cancer being used to train the model.
RESULTS: Compared with ground truth MC simulations, the predicted dose distributions by RapidBrachyDL showed a consistent shape in the dose-volume histograms (DVHs); comparable DVH dosimetric indices including 0.73% difference for prostate CTV D90, 1.1% for rectum D2cc, 1.45% for urethra D0.1cc, and 1.05% for bladder D2cc; and substantially smaller prediction time, acceleration by a factor of 300. RapidBrachyDL also demonstrated good generalization to cervical data with 1.73%, 2.46%, 1.68%, and 1.74% difference for CTV D90, rectum D2cc, sigmoid D2cc, and bladder D2cc, respectively, which was unseen during the training.
CONCLUSION: Deep CNN-based dose estimation is a promising method for patient-specific brachytherapy dosimetry. Desired radiation quantities can be obtained with accuracies arbitrarily close to those of the source MC algorithm, but with much faster computation times. The idea behind deep CNN-based dose estimation can be safely extended to other radiation sources and tumor sites by following a similar training process.
Famulari, Gabriel; Alfieri, Joanne; Duclos, Marie; Vuong, Té; Enger, Shirin A.
Can intermediate-energy sources lead to elevated bone doses for prostate and head & neck high-dose-rate brachytherapy? Journal Article
In: Brachytherapy, vol. 19, no. 2, pp. 255–263, 2020, ISSN: 1873-1449.
Abstract | Links | BibTeX | Tags: Bone and Bones, Brachytherapy, Cobalt Radioisotopes, Computer Simulation, Computer-Assisted, Dose calculation, Gadolinium, Humans, Intermediate-energy source, Iridium Radioisotopes, Male, Monte Carlo, Prostatic Neoplasms, Radiation Dosage, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Selenium Radioisotopes, Tissue composition, Tongue Neoplasms, Ytterbium
@article{famulari_can_2020,
title = {Can intermediate-energy sources lead to elevated bone doses for prostate and head & neck high-dose-rate brachytherapy?},
author = {Gabriel Famulari and Joanne Alfieri and Marie Duclos and Té Vuong and Shirin A. Enger},
doi = {10.1016/j.brachy.2019.12.004},
issn = {1873-1449},
year = {2020},
date = {2020-04-01},
journal = {Brachytherapy},
volume = {19},
number = {2},
pages = {255--263},
abstract = {PURPOSE: Several radionuclides with high (60Co, 75Se) and intermediate (169Yb, 153Gd) energies have been investigated as alternatives to 192Ir for high-dose-rate brachytherapy. The purpose of this study was to evaluate the impact of tissue heterogeneities for these five high- to intermediate-energy sources in prostate and head & neck brachytherapy. METHODS AND MATERIALS: Treatment plans were generated for a cohort of prostate (n = 10) and oral tongue (n = 10) patients. Dose calculations were performed using RapidBrachyMCTPS, an in-house Geant4-based Monte Carlo treatment planning system. Treatment plans were simulated using 60Co, 192Ir, 75Se, 169Yb, and 153Gd as the active core of the microSelectron v2 source. Two dose calculation scenarios were presented: (1) dose to water in water (Dw,w), and (2) dose to medium in medium (Dm,m).
RESULTS: Dw,w overestimates planning target volume coverage compared with Dm,m, regardless of photon energy. The average planning target volume D90 reduction was ∼1% for high-energy sources, whereas larger differences were observed for intermediate-energy sources (1%-2% for prostate and 4%-7% for oral tongue). Dose differences were not clinically relevant (textless5%) for soft tissues in general. Going from Dw,w to Dm,m, bone doses were increased two- to three-fold for 169Yb and four- to five-fold for 153Gd, whereas the ratio was close to ∼1 for high-energy sources.
CONCLUSIONS: Dw,w underestimates the dose to bones and, to a lesser extent, overestimates the dose to soft tissues for radionuclides with average energies lower than 192Ir. Further studies regarding bone toxicities are needed before intermediate-energy sources can be adopted in cases where bones are in close vicinity to the tumor.},
keywords = {Bone and Bones, Brachytherapy, Cobalt Radioisotopes, Computer Simulation, Computer-Assisted, Dose calculation, Gadolinium, Humans, Intermediate-energy source, Iridium Radioisotopes, Male, Monte Carlo, Prostatic Neoplasms, Radiation Dosage, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Selenium Radioisotopes, Tissue composition, Tongue Neoplasms, Ytterbium},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Several radionuclides with high (60Co, 75Se) and intermediate (169Yb, 153Gd) energies have been investigated as alternatives to 192Ir for high-dose-rate brachytherapy. The purpose of this study was to evaluate the impact of tissue heterogeneities for these five high- to intermediate-energy sources in prostate and head & neck brachytherapy. METHODS AND MATERIALS: Treatment plans were generated for a cohort of prostate (n = 10) and oral tongue (n = 10) patients. Dose calculations were performed using RapidBrachyMCTPS, an in-house Geant4-based Monte Carlo treatment planning system. Treatment plans were simulated using 60Co, 192Ir, 75Se, 169Yb, and 153Gd as the active core of the microSelectron v2 source. Two dose calculation scenarios were presented: (1) dose to water in water (Dw,w), and (2) dose to medium in medium (Dm,m).
RESULTS: Dw,w overestimates planning target volume coverage compared with Dm,m, regardless of photon energy. The average planning target volume D90 reduction was ∼1% for high-energy sources, whereas larger differences were observed for intermediate-energy sources (1%-2% for prostate and 4%-7% for oral tongue). Dose differences were not clinically relevant (textless5%) for soft tissues in general. Going from Dw,w to Dm,m, bone doses were increased two- to three-fold for 169Yb and four- to five-fold for 153Gd, whereas the ratio was close to ∼1 for high-energy sources.
CONCLUSIONS: Dw,w underestimates the dose to bones and, to a lesser extent, overestimates the dose to soft tissues for radionuclides with average energies lower than 192Ir. Further studies regarding bone toxicities are needed before intermediate-energy sources can be adopted in cases where bones are in close vicinity to the tumor.
RESULTS: Dw,w overestimates planning target volume coverage compared with Dm,m, regardless of photon energy. The average planning target volume D90 reduction was ∼1% for high-energy sources, whereas larger differences were observed for intermediate-energy sources (1%-2% for prostate and 4%-7% for oral tongue). Dose differences were not clinically relevant (textless5%) for soft tissues in general. Going from Dw,w to Dm,m, bone doses were increased two- to three-fold for 169Yb and four- to five-fold for 153Gd, whereas the ratio was close to ∼1 for high-energy sources.
CONCLUSIONS: Dw,w underestimates the dose to bones and, to a lesser extent, overestimates the dose to soft tissues for radionuclides with average energies lower than 192Ir. Further studies regarding bone toxicities are needed before intermediate-energy sources can be adopted in cases where bones are in close vicinity to the tumor.
Famulari, Gabriel; Duclos, Marie; Enger, Shirin A.
A novel 169 Yb-based dynamic-shield intensity modulated brachytherapy delivery system for prostate cancer Journal Article
In: Medical Physics, vol. 47, no. 3, pp. 859–868, 2020, ISSN: 2473-4209.
Abstract | Links | BibTeX | Tags: Brachytherapy, Cohort Studies, Computer-Assisted, Humans, IMBT, Intensity-Modulated, Male, Monte Carlo, Monte Carlo Method, prostate cancer, Prostatic Neoplasms, Radioisotopes, Radiotherapy, Radiotherapy Planning, Uncertainty, Yb-169, Ytterbium
@article{famulari_novel_2020,
title = {A novel 169 Yb-based dynamic-shield intensity modulated brachytherapy delivery system for prostate cancer},
author = {Gabriel Famulari and Marie Duclos and Shirin A. Enger},
doi = {10.1002/mp.13959},
issn = {2473-4209},
year = {2020},
date = {2020-03-01},
journal = {Medical Physics},
volume = {47},
number = {3},
pages = {859--868},
abstract = {PURPOSE: Intensity modulated brachytherapy (IMBT) is a novel high dose rate brachytherapy (HDR BT) technique which incorporates static or dynamic shielding to increase tumor coverage and/or spare healthy tissues. The purpose of this study is to present a novel delivery system (AIM-Brachy) design that can enable dynamic-shield IMBT for prostate cancer.
METHODS: The AIM-Brachy system dynamically controls the rotation of platinum shields, placed within interstitial catheters, which partially collimate the radiation emitted from an 169 Yb source. Conventional HDR BT (10 Ci 192 Ir) and IMBT (18 Ci 169 Yb) plans were generated for 12 patients using an in-house column generation-based optimizer, coupled to a Geant4-based dose calculation engine, RapidBrachyMC. Treatment plans were normalized to match the same PTV D90 coverage as the clinical plan. Intershield attenuation effects were taken into account. A sensitivity analysis was performed to evaluate the dosimetric impact of systematic longitudinal source positioning errors ( ± 1 mm, ± 2 mm, and ± 3 mm) and rotational errors ( ± 5 ∘ , ± 10 ∘ , and ± 15 ∘ ) on clinically relevant parameters (PTV D90 and urethra D10 ).
RESULTS: The platinum shield reduced the dose rate on the shielded side at 1 cm to 18.1% of the dose rate on the unshielded side. For equal PTV D90 coverage, the urethral D10 was reduced by 13.3% ± 4.7%, without change to other plan quality indices (PTV V100 , V150, V200 , bladder V75 , rectum V75 , HI, COIN). Delivery times for HDR BT and IMBT were 9.2 ± 1.6 min and 18.6 ± 4.0 min, respectively. In general, the PTV D90 was more sensitive to source positioning errors than rotational errors, while the urethral D10 was more sensitive to rotational errors than source positioning errors. For a typical range of positioning errors ( ± 1 mm, ± 5 ∘ ), the overall tolerance was textless2%.
CONCLUSIONS: The AIM-Brachy system was proposed to deliver dynamic-shield IMBT for prostate cancer with the potential to create a low dose tunnel within the urethra. The urethra-sparing properties are desirable to minimize the occurrence and severity of urethral strictures or, alternatively, to provide a method for dose escalation.},
keywords = {Brachytherapy, Cohort Studies, Computer-Assisted, Humans, IMBT, Intensity-Modulated, Male, Monte Carlo, Monte Carlo Method, prostate cancer, Prostatic Neoplasms, Radioisotopes, Radiotherapy, Radiotherapy Planning, Uncertainty, Yb-169, Ytterbium},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Intensity modulated brachytherapy (IMBT) is a novel high dose rate brachytherapy (HDR BT) technique which incorporates static or dynamic shielding to increase tumor coverage and/or spare healthy tissues. The purpose of this study is to present a novel delivery system (AIM-Brachy) design that can enable dynamic-shield IMBT for prostate cancer.
METHODS: The AIM-Brachy system dynamically controls the rotation of platinum shields, placed within interstitial catheters, which partially collimate the radiation emitted from an 169 Yb source. Conventional HDR BT (10 Ci 192 Ir) and IMBT (18 Ci 169 Yb) plans were generated for 12 patients using an in-house column generation-based optimizer, coupled to a Geant4-based dose calculation engine, RapidBrachyMC. Treatment plans were normalized to match the same PTV D90 coverage as the clinical plan. Intershield attenuation effects were taken into account. A sensitivity analysis was performed to evaluate the dosimetric impact of systematic longitudinal source positioning errors ( ± 1 mm, ± 2 mm, and ± 3 mm) and rotational errors ( ± 5 ∘ , ± 10 ∘ , and ± 15 ∘ ) on clinically relevant parameters (PTV D90 and urethra D10 ).
RESULTS: The platinum shield reduced the dose rate on the shielded side at 1 cm to 18.1% of the dose rate on the unshielded side. For equal PTV D90 coverage, the urethral D10 was reduced by 13.3% ± 4.7%, without change to other plan quality indices (PTV V100 , V150, V200 , bladder V75 , rectum V75 , HI, COIN). Delivery times for HDR BT and IMBT were 9.2 ± 1.6 min and 18.6 ± 4.0 min, respectively. In general, the PTV D90 was more sensitive to source positioning errors than rotational errors, while the urethral D10 was more sensitive to rotational errors than source positioning errors. For a typical range of positioning errors ( ± 1 mm, ± 5 ∘ ), the overall tolerance was textless2%.
CONCLUSIONS: The AIM-Brachy system was proposed to deliver dynamic-shield IMBT for prostate cancer with the potential to create a low dose tunnel within the urethra. The urethra-sparing properties are desirable to minimize the occurrence and severity of urethral strictures or, alternatively, to provide a method for dose escalation.
METHODS: The AIM-Brachy system dynamically controls the rotation of platinum shields, placed within interstitial catheters, which partially collimate the radiation emitted from an 169 Yb source. Conventional HDR BT (10 Ci 192 Ir) and IMBT (18 Ci 169 Yb) plans were generated for 12 patients using an in-house column generation-based optimizer, coupled to a Geant4-based dose calculation engine, RapidBrachyMC. Treatment plans were normalized to match the same PTV D90 coverage as the clinical plan. Intershield attenuation effects were taken into account. A sensitivity analysis was performed to evaluate the dosimetric impact of systematic longitudinal source positioning errors ( ± 1 mm, ± 2 mm, and ± 3 mm) and rotational errors ( ± 5 ∘ , ± 10 ∘ , and ± 15 ∘ ) on clinically relevant parameters (PTV D90 and urethra D10 ).
RESULTS: The platinum shield reduced the dose rate on the shielded side at 1 cm to 18.1% of the dose rate on the unshielded side. For equal PTV D90 coverage, the urethral D10 was reduced by 13.3% ± 4.7%, without change to other plan quality indices (PTV V100 , V150, V200 , bladder V75 , rectum V75 , HI, COIN). Delivery times for HDR BT and IMBT were 9.2 ± 1.6 min and 18.6 ± 4.0 min, respectively. In general, the PTV D90 was more sensitive to source positioning errors than rotational errors, while the urethral D10 was more sensitive to rotational errors than source positioning errors. For a typical range of positioning errors ( ± 1 mm, ± 5 ∘ ), the overall tolerance was textless2%.
CONCLUSIONS: The AIM-Brachy system was proposed to deliver dynamic-shield IMBT for prostate cancer with the potential to create a low dose tunnel within the urethra. The urethra-sparing properties are desirable to minimize the occurrence and severity of urethral strictures or, alternatively, to provide a method for dose escalation.
Enger, Shirin A.; Vijande, Javier; Rivard, Mark J.
Model-Based Dose Calculation Algorithms for Brachytherapy Dosimetry Journal Article
In: Seminars in Radiation Oncology, vol. 30, no. 1, pp. 77–86, 2020, ISSN: 1532-9461.
Abstract | Links | BibTeX | Tags: Algorithms, Brachytherapy, Computer-Assisted, Female, Humans, Male, Medical, Models, Neoplasms, Photons, Practice Guidelines as Topic, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Societies, Theoretical
@article{enger_model-based_2020,
title = {Model-Based Dose Calculation Algorithms for Brachytherapy Dosimetry},
author = {Shirin A. Enger and Javier Vijande and Mark J. Rivard},
doi = {10.1016/j.semradonc.2019.08.006},
issn = {1532-9461},
year = {2020},
date = {2020-01-01},
journal = {Seminars in Radiation Oncology},
volume = {30},
number = {1},
pages = {77--86},
abstract = {The purpose of this study was to review the limitations of dose calculation formalisms for photon-emitting brachytherapy sources based on the American Association of Physicists in Medicine (AAPM) Task Group No. 43 (TG-43) report and to provide recommendations to transition to model-based dose calculation algorithms. Additionally, an overview of these algorithms and approaches is presented. The influence of tissue and seed/applicator heterogeneities on brachytherapy dose distributions for breast, gynecologic, head and neck, rectum, and prostate cancers as well as eye plaques and electronic brachytherapy treatments were investigated by comparing dose calculations based on the TG-43 formalism and model-based dose calculation algorithms.},
keywords = {Algorithms, Brachytherapy, Computer-Assisted, Female, Humans, Male, Medical, Models, Neoplasms, Photons, Practice Guidelines as Topic, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Societies, Theoretical},
pubstate = {published},
tppubtype = {article}
}
The purpose of this study was to review the limitations of dose calculation formalisms for photon-emitting brachytherapy sources based on the American Association of Physicists in Medicine (AAPM) Task Group No. 43 (TG-43) report and to provide recommendations to transition to model-based dose calculation algorithms. Additionally, an overview of these algorithms and approaches is presented. The influence of tissue and seed/applicator heterogeneities on brachytherapy dose distributions for breast, gynecologic, head and neck, rectum, and prostate cancers as well as eye plaques and electronic brachytherapy treatments were investigated by comparing dose calculations based on the TG-43 formalism and model-based dose calculation algorithms.
2015
Poole, Christopher M.; Ahnesjö, Anders; Enger, Shirin A.
Determination of subcellular compartment sizes for estimating dose variations in radiotherapy Journal Article
In: Radiation Protection Dosimetry, vol. 166, no. 1-4, pp. 361–364, 2015, ISSN: 1742-3406.
Abstract | Links | BibTeX | Tags: Algorithms, Breast Neoplasms, Cell Nucleus, Computer Simulation, Computer-Assisted, ErbB-2, Female, Humans, Image Processing, Imaging, Immunoenzyme Techniques, Male, Monte Carlo Method, Prostatic Neoplasms, Radiotherapy Dosage, Radiotherapy Planning, Receptor, Signal Processing, Subcellular Fractions, Three-Dimensional
@article{poole_determination_2015,
title = {Determination of subcellular compartment sizes for estimating dose variations in radiotherapy},
author = {Christopher M. Poole and Anders Ahnesjö and Shirin A. Enger},
doi = {10.1093/rpd/ncv305},
issn = {1742-3406},
year = {2015},
date = {2015-09-01},
journal = {Radiation Protection Dosimetry},
volume = {166},
number = {1-4},
pages = {361--364},
abstract = {The variation in specific energy absorbed to different cell compartments caused by variations in size and chemical composition is poorly investigated in radiotherapy. The aim of this study was to develop an algorithm to derive cell and cell nuclei size distributions from 2D histology samples, and build 3D cellular geometries to provide Monte Carlo (MC)-based dose calculation engines with a morphologically relevant input geometry. Stained and unstained regions of the histology samples are segmented using a Gaussian mixture model, and individual cell nuclei are identified via thresholding. Delaunay triangulation is applied to determine the distribution of distances between the centroids of nearest neighbour cells. A pouring simulation is used to build a 3D virtual tissue sample, with cell radii randomised according to the cell size distribution determined from the histology samples. A slice with the same thickness as the histology sample is cut through the 3D data and characterised in the same way as the measured histology. The comparison between this virtual slice and the measured histology is used to adjust the initial cell size distribution into the pouring simulation. This iterative approach of a pouring simulation with adjustments guided by comparison is continued until an input cell size distribution is found that yields a distribution in the sliced geometry that agrees with the measured histology samples. The thus obtained morphologically realistic 3D cellular geometry can be used as input to MC-based dose calculation programs for studies of dose response due to variations in morphology and size of tumour/healthy tissue cells/nuclei, and extracellular material.},
keywords = {Algorithms, Breast Neoplasms, Cell Nucleus, Computer Simulation, Computer-Assisted, ErbB-2, Female, Humans, Image Processing, Imaging, Immunoenzyme Techniques, Male, Monte Carlo Method, Prostatic Neoplasms, Radiotherapy Dosage, Radiotherapy Planning, Receptor, Signal Processing, Subcellular Fractions, Three-Dimensional},
pubstate = {published},
tppubtype = {article}
}
The variation in specific energy absorbed to different cell compartments caused by variations in size and chemical composition is poorly investigated in radiotherapy. The aim of this study was to develop an algorithm to derive cell and cell nuclei size distributions from 2D histology samples, and build 3D cellular geometries to provide Monte Carlo (MC)-based dose calculation engines with a morphologically relevant input geometry. Stained and unstained regions of the histology samples are segmented using a Gaussian mixture model, and individual cell nuclei are identified via thresholding. Delaunay triangulation is applied to determine the distribution of distances between the centroids of nearest neighbour cells. A pouring simulation is used to build a 3D virtual tissue sample, with cell radii randomised according to the cell size distribution determined from the histology samples. A slice with the same thickness as the histology sample is cut through the 3D data and characterised in the same way as the measured histology. The comparison between this virtual slice and the measured histology is used to adjust the initial cell size distribution into the pouring simulation. This iterative approach of a pouring simulation with adjustments guided by comparison is continued until an input cell size distribution is found that yields a distribution in the sliced geometry that agrees with the measured histology samples. The thus obtained morphologically realistic 3D cellular geometry can be used as input to MC-based dose calculation programs for studies of dose response due to variations in morphology and size of tumour/healthy tissue cells/nuclei, and extracellular material.
2014
Adams, Quentin E.; Xu, Jinghzu; Breitbach, Elizabeth K.; Li, Xing; Enger, Shirin A.; Rockey, William R.; Kim, Yusung; Wu, Xiaodong; Flynn, Ryan T.
Interstitial rotating shield brachytherapy for prostate cancer Journal Article
In: Medical Physics, vol. 41, no. 5, pp. 051703, 2014, ISSN: 2473-4209.
Abstract | Links | BibTeX | Tags: Brachytherapy, Catheters, Computer-Assisted, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Needles, Nickel, Platinum Compounds, Prostatic Neoplasms, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Time Factors, Titanium, Urethra, Urinary Bladder
@article{adams_interstitial_2014,
title = {Interstitial rotating shield brachytherapy for prostate cancer},
author = {Quentin E. Adams and Jinghzu Xu and Elizabeth K. Breitbach and Xing Li and Shirin A. Enger and William R. Rockey and Yusung Kim and Xiaodong Wu and Ryan T. Flynn},
doi = {10.1118/1.4870441},
issn = {2473-4209},
year = {2014},
date = {2014-05-01},
journal = {Medical Physics},
volume = {41},
number = {5},
pages = {051703},
abstract = {PURPOSE: To present a novel needle, catheter, and radiation source system for interstitial rotating shield brachytherapy (I-RSBT) of the prostate. I-RSBT is a promising technique for reducing urethra, rectum, and bladder dose relative to conventional interstitial high-dose-rate brachytherapy (HDR-BT).
METHODS: A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%.
RESULTS: The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources.
CONCLUSIONS: For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.},
keywords = {Brachytherapy, Catheters, Computer-Assisted, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Needles, Nickel, Platinum Compounds, Prostatic Neoplasms, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Time Factors, Titanium, Urethra, Urinary Bladder},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: To present a novel needle, catheter, and radiation source system for interstitial rotating shield brachytherapy (I-RSBT) of the prostate. I-RSBT is a promising technique for reducing urethra, rectum, and bladder dose relative to conventional interstitial high-dose-rate brachytherapy (HDR-BT).
METHODS: A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%.
RESULTS: The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources.
CONCLUSIONS: For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.
METHODS: A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%.
RESULTS: The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources.
CONCLUSIONS: For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.
2013
Enger, Shirin A.; Fisher, Darrell R.; Flynn, Ryan T.
Gadolinium-153 as a brachytherapy isotope Journal Article
In: Physics in Medicine and Biology, vol. 58, no. 4, pp. 957–964, 2013, ISSN: 1361-6560.
Abstract | Links | BibTeX | Tags: Anisotropy, Brachytherapy, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Photons, Prostatic Neoplasms, Radiation, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Scattering
@article{enger_gadolinium-153_2013,
title = {Gadolinium-153 as a brachytherapy isotope},
author = {Shirin A. Enger and Darrell R. Fisher and Ryan T. Flynn},
doi = {10.1088/0031-9155/58/4/957},
issn = {1361-6560},
year = {2013},
date = {2013-02-01},
journal = {Physics in Medicine and Biology},
volume = {58},
number = {4},
pages = {957--964},
abstract = {The purpose of this work was to present the fundamental dosimetric characteristics of a hypothetical (153)Gd brachytherapy source using the AAPM TG-43U1 dose-calculation formalism. Gadolinium-153 is an intermediate-energy isotope that emits 40-100 keV photons with a half-life of 242 days. The rationale for considering (153)Gd as a brachytherapy source is for its potential of patient specific shielding and to enable reduced personnel shielding requirements relative to (192)Ir, and as an isotope for interstitial rotating shield brachytherapy (I-RSBT). A hypothetical (153)Gd brachytherapy source with an active core of 0.84 mm diameter, 10 mm length and specific activity of 5.55 TBq of (153)Gd per gram of Gd was simulated with Geant4. The encapsulation material was stainless steel with a thickness of 0.08 mm. The radial dose function, anisotropy function and photon spectrum in water were calculated for the (153)Gd source. The simulated (153)Gd source had an activity of 242 GBq and a dose rate in water 1 cm off axis of 13.12 Gy h(-1), indicating that it would be suitable as a low-dose-rate or pulsed-dose-rate brachytherapy source. The beta particles emitted have low enough energies to be absorbed in the source encapsulation. Gadolinium-153 has an increasing radial dose function due to multiple scatter of low-energy photons. Scattered photon dose takes over with distance from the source and contributes to the majority of the absorbed dose. The anisotropy function of the (153)Gd source decreases at low polar angles, as a result of the long active core. The source is less anisotropic at polar angles away from the longitudinal axes. The anisotropy function increases with increasing distance. The (153)Gd source considered would be suitable as an intermediate-energy low-dose-rate or pulsed-dose-rate brachytherapy source. The source could provide a means for I-RSBT delivery and enable brachytherapy treatments with patient specific shielding and reduced personnel shielding requirements relative to (192)Ir.},
keywords = {Anisotropy, Brachytherapy, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Photons, Prostatic Neoplasms, Radiation, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Scattering},
pubstate = {published},
tppubtype = {article}
}
The purpose of this work was to present the fundamental dosimetric characteristics of a hypothetical (153)Gd brachytherapy source using the AAPM TG-43U1 dose-calculation formalism. Gadolinium-153 is an intermediate-energy isotope that emits 40-100 keV photons with a half-life of 242 days. The rationale for considering (153)Gd as a brachytherapy source is for its potential of patient specific shielding and to enable reduced personnel shielding requirements relative to (192)Ir, and as an isotope for interstitial rotating shield brachytherapy (I-RSBT). A hypothetical (153)Gd brachytherapy source with an active core of 0.84 mm diameter, 10 mm length and specific activity of 5.55 TBq of (153)Gd per gram of Gd was simulated with Geant4. The encapsulation material was stainless steel with a thickness of 0.08 mm. The radial dose function, anisotropy function and photon spectrum in water were calculated for the (153)Gd source. The simulated (153)Gd source had an activity of 242 GBq and a dose rate in water 1 cm off axis of 13.12 Gy h(-1), indicating that it would be suitable as a low-dose-rate or pulsed-dose-rate brachytherapy source. The beta particles emitted have low enough energies to be absorbed in the source encapsulation. Gadolinium-153 has an increasing radial dose function due to multiple scatter of low-energy photons. Scattered photon dose takes over with distance from the source and contributes to the majority of the absorbed dose. The anisotropy function of the (153)Gd source decreases at low polar angles, as a result of the long active core. The source is less anisotropic at polar angles away from the longitudinal axes. The anisotropy function increases with increasing distance. The (153)Gd source considered would be suitable as an intermediate-energy low-dose-rate or pulsed-dose-rate brachytherapy source. The source could provide a means for I-RSBT delivery and enable brachytherapy treatments with patient specific shielding and reduced personnel shielding requirements relative to (192)Ir.